At the Annual General Meeting of 8 May 2020, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September 2020.

 The Nomination Committee for the 2021 Annual General Meetings consists of:

Mats Johansson;

Hans Karlsson Höiden, appointed by Orest Lastow;

Stefan Berger, appointed by Eiffel Investment Group;

Johan Lundgren, Chair of the Nomination Committee

The Nomination Committee’s overarching responsibility for the 2021 Annual General Meeting is to present suitable candidates for the positions of Board Chair, Board members and auditor (s) of the Company, and to propose their remuneration.

 The Nomination Committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for decision:

proposal for Chair of the AGM,

proposal for the number of AGM-elected Board members and, where applicable, number of auditors,

proposal for remuneration to non-employed members of the Board and to non-employed members of the various committees of the Board,

proposal for remuneration to the auditors,

proposals for election of Board Chair, other members of the Board and, where applicable, auditors,

proposals for guidelines for appointing members to the Nomination Committee and for the Nomination Committee’s assignments,

proposal for remuneration to the members of the Nomination Committee.

 

Shareholders who wish to submit proposals to the Nomination Committee can contact the Nomination Committee by email at Johan.Lundgren@zenitdesign.se.

In order for the Nomination Committee to process received proposals with sufficient care, these should be received by the Nomination Committee by 1 March 2021.

LUND, 17 NOVEMBER 2020

BOARD OF DIRECTORS

Contact Nomination committee

Mats Johansson, Chairman of the Board
mats.johansson@abraxasholding.com 

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

Nomination Committee appointed at Iconovo

© Modular Finance, source Nordic Press Releases